NCT01140178 is a Phase 1 clinical trial of HPPH in Dysplasia, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT01140178?

NCT01140178 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT01140178?

Interventions in NCT01140178: HPPH.

What condition does NCT01140178 study?

NCT01140178 studies Dysplasia, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx.

Is NCT01140178 still recruiting?

NCT01140178 is currently completed. Last updated 16 October 2018.

Last reviewed 2018-10-16 · How we verify

NCT01140178

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Completed Phase 1 Last updated 16 October 2018

What this trial tests

Phase 1 trial testing HPPH in Dysplasia in 29 participants. Completed in 1 October 2018.

Timeline

8 June 2010

Primary endpoint
29 January 2013

1 October 2018

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	8 June 2010
Primary completion	29 January 2013
Estimated completion	1 October 2018
Sites	1 location across United States

Drugs / interventions tested

HPPH — full drug profile →

Conditions studied

Dysplasia — all drugs for Dysplasia →
Carcinoma of the Oral Cavity — all drugs for Carcinoma of the Oral Cavity →
Carcinoma of the Oropharynx — all drugs for Carcinoma of the Oropharynx →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, any sex, with Dysplasia or Carcinoma of the Oral Cavity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recent literature suggests that certain patients with squamous cell cancers of the head and neck region may benefit from photodynamic therapy whether or not they may have received prior therapy, e.g. radiation therapy

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Dye Sensitizers for Photodynamic Therapy.
Ormond AB, Freeman HS. · · 2013 · cited 403× · PMID 28809342 · DOI 10.3390/ma6030817
Biocompatible Nanocarriers for Enhanced Cancer Photodynamic Therapy Applications.
Dhilip Kumar SS, Abrahamse H. · · 2021 · cited 21× · PMID 34834348 · DOI 10.3390/pharmaceutics13111933
Design and biological activity of novel stealth polymeric lipid nanoparticles for enhanced delivery of hydrophobic photodynamic therapy drugs.
Viard M, Reichard H, Shapiro BA, Durrani FA, et al · · 2018 · cited 13× · PMID 30059754 · DOI 10.1016/j.nano.2018.07.006

Verify or expand the search:

Other trials of HPPH

Trials testing the same drug.

NCT03090412 — Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer · Phase 2 · terminated
NCT00675233 — Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx · Phase 1 · completed
NCT00470496 — Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer · Phase 1 · completed

Other recruiting trials for Dysplasia

Currently open trials in the same condition.

NCT06370143 — A Study Collecting Health Information to Understand and Prevent Gastric Cancer · recruiting
NCT06266104 — Image Enhanced Endoscopy IBD · NA · recruiting
NCT06281392 — Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study) · NA · active not recruiting
NCT06430372 — Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract · Phase 1 · recruiting
NCT05809999 — IBD Neoplasia Surveillance RCT · NA · recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01140178 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 16 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01140178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing